U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07446257) titled 'THIO and Cadonilimab in Resectable Hepatocellular Carcinoma' on Jan. 29.
Brief Summary: The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Resectable Hepatocellular Carcinoma
Intervention:
DRUG: ateganosine
ateganosine: 180 mg IV D1, D2, D3 of 21-day cycle
DRUG: Cadonilimab
cadonilimab: 10 mg/kg IV D5 of 21-day cycle
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Texas Southwestern Medical Center
Information provided by (Respo...